Mario Andrea Piga

Mario Andrea Piga

Auto-generated profile, based on publicly available information

Mario Andrea Piga

National PhD Course in Precision Medicine in Rare Diseases University of Palermo Palermo Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
MDMaria Giovanna Danieli
Maria Giovanna Danieli
MPMario Andrea Piga
Mario Andrea Piga
APAlberto Paladini
Alberto Paladini
ELEleonora Longhi
Eleonora Longhi
CMCristina Mezzanotte
Cristina Mezzanotte
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
The coronavirus disease‐19 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple‐organ failure. The so‐called ‘cytokines storm’ is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID‐19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID‐19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID‐19 and anti‐SARS‐CoV‐2 vaccination related autoimmune diseases and the post‐COVID‐19 syndrome. The benefit of high‐dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID‐19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies’ limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.

13 October 2025 in Allergy
Verified
Journal Article
Closed access
MMMatteo Martini
Matteo Martini
LALeonardo Antonicelli
Leonardo Antonicelli
MGMaria Stella Garritani
Maria Stella Garritani
MBMaria Chiara Braschi
Maria Chiara Braschi
AVAngelica Di Vincenzo
Angelica Di Vincenzo
MBMaria Beatrice Bilõ
Maria Beatrice Bilõ